Placeholder Banner

BIO submits comments to USDA’s Animal and Plant Health Inspection Service RE: Availability of an Environmental Assessment for the Field Release of Genetically Engineered Diamondback Moths

May 25, 2017

May 19, 2017

Docket No. APHIS-2014-0056
Regulatory Analysis and Development
Plant Protection Division - APHIS
Station 3A–03.8
4700 River Road Unit 118
Riverdale, MD 20737–1238.
http://www.regulations.gov/#!docketDetail;D=APHIS-2014-0056

Re: Animal and Plant Health Inspection Service Docket No. APHIS–2014–0056; Availability of an Environmental Assessment for the Field Release of Genetically Engineered Diamondback Moths

To Whom It May Concern:

The Biotechnology Innovation Organization (BIO) appreciates this opportunity to provide comments to the United States Department of Agriculture (USDA) Animal Plant Health Inspection Service (APHIS). BIO is the world's largest biotechnology trade association, representing small and large companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. BIO represents its members in a number of matters related to agricultural biotechnology, and in particular, has a strong interest in the sound regulation of animal biotechnology. These comments by BIO address the environmental assessment for the field release of genetically engineered diamondback moths and further support BIO’s advocacy for the sound regulation of animal biotechnology.

APHIS prepared this environmental assessment (EA) in response to Cornell University’s application for a permit1 to conduct an experimental release of the genetically engineered (GE) diamondback moth (Plutella xylostella) strain OX4319L-Pxy. Pursuant to the National Environmental Policy Act of 1969 (NEPA), APHIS thoroughly assessed the potential impacts of its decision to grant or deny a permit on key resource areas: human health, the physical and biotic environments, including threatened and endangered species. BIO concurs with the factual accuracy, scientific validity and thoroughness of APHIS’s review and, therefore agrees with the scope, analysis and conclusions described in the EA...

Download Full Comments Below
BIO Comments To USDA Animal And Plant Health Inspection Service
Read full comments below:
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…